Please wait a minute...
Frontiers of Medicine

ISSN 2095-0217

ISSN 2095-0225(Online)

CN 11-5983/R

Postal Subscription Code 80-967

2018 Impact Factor: 1.847

Front. Med.    2010, Vol. 4 Issue (1) : 67-70    https://doi.org/10.1007/s11684-010-0023-8
Research articles
Effectiveness of lifestyle intervention for hypertension in Shanghai communities: Results from the Shanghai Hypertension Detail Management Program
Xin-Jian LI MD,Min-Na CHENG MPH,Yu-Heng WANG MD,Sun MIAO MPH,Zong-Qi ZHANG PhD,Yi-Sheng CHEN MD,Wei LU PhD,
Department of Cardiovascular Disease Prevention, Shanghai Municipal Center for Disease Control and Prevention, Shanghai 200336, China;
 Download: PDF(92 KB)  
 Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract A community-based multi-center randomized controlled trial was conducted to evaluate the effectiveness of blood pressure control for hypertension patients in communities in urban Shanghai by integrated intervention. At present, patients (n=1395) from four communities have completed follow-up for one year, including the intervention group (n=921) and usual care group (n=474). The intervention programs included disease management by a care manager. Blood pressure of each patient was measured regularly. Compared with the control group, the net change of mean systolic blood pressure (SBP) was −6.75 (95% CI: −7.79 to −5.71, P<0.001) mmHg, mean diastolic blood pressure (DBP) was −4.29 (95% CI: −5.08 to −3.49, P<0.001) mmHg, and mean pulse pressure (PP) was −2.46 (95% CI: −3.50 to −1.43, P<0.001) mmHg in the intervention group. The net change extent was larger in patients with regular pharmacological treatment than in those with irregular pharmacological treatment or non-pharmacological treatment. The measures of integrated intervention for hypertension patients in communities can lower significantly not only SBP and DBP, but also PP. It is suggested that measures of integrated intervention can decrease the risk of cardiovascular diseases in hypertension patients.
Keywords hypertension      community      pharmacological adherence      control of blood pressure      
Issue Date: 05 March 2010
 Cite this article:   
Zong-Qi ZHANG PhD,Xin-Jian LI MD,Yu-Heng WANG MD, et al. Effectiveness of lifestyle intervention for hypertension in Shanghai communities: Results from the Shanghai Hypertension Detail Management Program[J]. Front. Med., 2010, 4(1): 67-70.
 URL:  
https://academic.hep.com.cn/fmd/EN/10.1007/s11684-010-0023-8
https://academic.hep.com.cn/fmd/EN/Y2010/V4/I1/67
Staessen J, Wang J G, Thijs L. Cardiovascular protection and blood pressurereduction: a meta-analysis. Lancet, 2001, 358 (9290): 1350―1315

doi: 10.1016/S0140-6736(01)06411-X
Reversing Committee ofGuide for Chinese Hypertension Prevention. Guide for Chinese Hypertension Prevention (2005 edition). Beijing: People’s Health Publishing House, 2006
Wang W, Zhao D, Sun J Y, Wang W H, Cheng J, Liu J, Qin L P, Liu S, Wu Z S. Risk factors comparison in Chinese patients developing acute coronarysyndrome, ischemic or hemorrhagic stroke: a multi-provincial cohortstudy. Zhonghua Xin Xue Guan Bing Za Zhi, 2006, 34(12): 1133―1137 (in Chinese)
Huang J R, He C Y, Bian C Y. Outcome of comprehensive preventive measuresfor hypertension: 6 years follow up. ZhonghuaGao Xue Ya Za Zhi, 2007, 15(1): 22―25 (in Chinese)
Mattila R, Malmivaara A, Kastarinen M, Kivel? S L, Nissinen A. Effectiveness of multidisciplinary lifestyle intervention for hypertension:a randomized controlled trial. J Hum Hypertens, 2003, 17 (3): 199―205

doi: 10.1038/sj.jhh.1001531
Kastarinen M J, Puska P M, Korhonen M H, Mustonen J N, Salomaa V V, Sundvall J E, Tuomilehto J O, Uusitupa M I, Nissinen A M; LIHEF Study Group. Non-pharmacologicaltreatment of hypertension in primary health care: a 2-year open randomizedcontrolled trial of lifestyle intervention against hypertension ineastern Finland. J Hypertens, 2002, 20(12): 2505―2512

doi: 10.1097/00004872-200212000-00031
Wang S Q. A community-based prospective control study of comprehensiveintervention in hypertension patients. Zhonghua Nei Ke Za Zhi, 2002, 41(3): 168―171 (in Chinese)
Gao J M, Wu X G, Zhu Y, Gu D F, Wang S Y, Wang H, Zhou J, Cao T X, Zhang X F, Cui S Z, Liu J T. Initial assessment of the efficacy of comprehensive interventionfor hypertension and its risk factors in male workers of iron andsteel plant. Zhonghua Xin Xue Guan BingZa Zhi, 1998, 26(2): 101―104 (in Chinese)
Franklin S S, Larson M G, Khan S A, Wong N D, Leip E P, Kannel W B, Levy D. Does the relationof blood pressure to coronary heart disease risk change with aging?The Framingham Heart Study. Circulation, 2001, 103 (9): 1245―1249
Zhang Q F, Park J K, Sang B, Kim C B, Chang S J. Relation between pulse pressureand cardio-cerebralvascular disease. ZhonghuaGao Xue Ya Za Zhi, 2006, 14(10): 830―832 (in Chinese)
Sun J, Lin Q, Liang W, Wu C, Jin C Y. Correlation analysis of pulsepressure with cardiac-cerebral vascular events in middle-aged andelderly patients with primary hypertension. Shanghai Yixue, 2008, 31(7): 470―473 (in Chinese)
[1] Jiuyang Xu, Chaolin Huang, Guohui Fan, Zhibo Liu, Lianhan Shang, Fei Zhou, Yeming Wang, Jiapei Yu, Luning Yang, Ke Xie, Zhisheng Huang, Lixue Huang, Xiaoying Gu, Hui Li, Yi Zhang, Yimin Wang, Frederick G. Hayden, Peter W. Horby, Bin Cao, Chen Wang. Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis[J]. Front. Med., 2020, 14(5): 601-612.
[2] Junjun Jia, Xinyao Tian, Jianwen Jiang, Zhigang Ren, Haifeng Lu, Ning He, Haiyang Xie, Lin Zhou, Shusen Zheng. Structural shifts in the intestinal microbiota of rats treated with cyclosporine A after orthotropic liver transplantation[J]. Front. Med., 2019, 13(4): 451-460.
[3] Ruoxi Zhang, Jing Chen, Diangang Liu, Yu Wang. Urotensin II receptor antagonist reduces hepatic resistance and portal pressure through enhanced eNOS-dependent HSC vasodilatation in CCl4-induced cirrhotic rats[J]. Front. Med., 2019, 13(3): 398-408.
[4] Xiuxiu Wu, Wenshuai Xu, Jun Wang, Xinlun Tian, Zhuang Tian, Kaifeng Xu. Clinical characteristics in lymphangioleiomyomatosis-related pulmonary hypertension: an observation on 50 patients[J]. Front. Med., 2019, 13(2): 259-266.
[5] Zhiwei Hu,Meiping Chen,Jimin Wu,Qing Song,Chao Yan,Xing Du,Zhonggao Wang. Improved control of hypertension following laparoscopic fundoplication for gastroesophageal reflux disease[J]. Front. Med., 2017, 11(1): 68-73.
[6] Lan Wang,Sen Jiang,Jingyun Shi,Sugang Gong,Qinhua Zhao,Rong Jiang,Ping Yuan,Bigyan Pudasaini,Jing He,Zhicheng Jing,Jinming Liu. Clinical characteristics of pulmonary hypertension in bronchiectasis[J]. Front. Med., 2016, 10(3): 336-344.
[7] Huiqin Zhong,Ya Shao,Ling Fan,Tangshen Zhong,Lu Ren,Yan Wang. Perceived resource support for chronic illnesses among diabetics in north-western China[J]. Front. Med., 2016, 10(2): 219-227.
[8] Dan Wu,Qingxun Hu,Yizhun Zhu. Therapeutic application of hydrogen sulfide donors: the potential and challenges[J]. Front. Med., 2016, 10(1): 18-27.
[9] Lichun Zhong. A modified chronic ocular hypertension rat model for retinal ganglion cell neuroprotection[J]. Front Med, 2013, 7(3): 367-377.
[10] Zhiming Zhu, Peijian Wang, Shuangtao Ma. Metabolic hypertension: concept and practice[J]. Front Med, 2013, 7(2): 201-206.
[11] Lulu Ma, Wei Liu, Yuguang Huang. Perioperative management for parturients with pulmonary hypertension: experience with 30 consecutive cases[J]. Front Med, 2012, 6(3): 307-310.
[12] Xinjian Li, Jiying Xu, Haihong Yao, Yanfei Guo, Minna Chen, Wei Lu. Obesity and overweight prevalence and its association with undiagnosed hypertension in Shanghai population, China: a cross-sectional population-based survey[J]. Front Med, 2012, 6(3): 322-328.
[13] Kan ZHANG MM, Wei DONG MM, Ying-Yao CHEN MD, . The next step of community health construction: Training general practitioners and implementing health management[J]. Front. Med., 2010, 4(2): 134-138.
[14] HUA Rong, SUN Yongwei, WU Zhiyong. Effects of combined procedure and devascularization alone on hyperdynamics of the portal venous system in patients with portal hypertension[J]. Front. Med., 2008, 2(3): 244-247.
[15] WANG Zhiqiang. Analysis of the treatment outcomes of esophageal variceal bleeding patients from multiple centers in China[J]. Front. Med., 2008, 2(2): 171-173.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed